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Abstract
Background: A large proportion of patients with coronavirus disease 2019 (COVID-19) develop severe respiratory failure
requiring admission to the intensive care unit (ICU) and about 80% of them need mechanical ventilation (MV). These
patients show great complexity due to multiple organ involvement and a dynamic evolution over time; moreover, few
information is available about the risk factors that may contribute to increase the time course of mechanical ventilation.
The primary objective of this study is to investigate the risk factors associated with the inability to liberate COVID-19
patients from mechanical ventilation. Due to the complex evolution of the disease, we analyzed both pulmonary
variables and occurrence of non-pulmonary complications during mechanical ventilation. The secondary objective of this
study was the evaluation of risk factors for ICU mortality.
Methods: This multicenter prospective observational study enrolled 391 patients from fifteen COVID-19 dedicated Italian
ICUs which underwent invasive mechanical ventilation for COVID-19 pneumonia. Clinical and laboratory data, ventilator
parameters, occurrence of organ dysfunction, and outcome were recorded. The primary outcome measure was 28 days
ventilator-free days and the liberation from MV at 28 days was studied by performing a competing risks regression model
on data, according to the method of Fine and Gray; the event death was considered as a competing risk.
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Results: Liberation from mechanical ventilation was achieved in 53.2% of the patients (208/391). Competing risks analysis,
considering death as a competing event, demonstrated a decreased sub-hazard ratio for liberation from mechanical
ventilation (MV) with increasing age and SOFA score at ICU admission, low values of PaO2/FiO2 ratio during the first 5
days of MV, respiratory system compliance (CRS) lower than 40mL/cmH2O during the first 5 days of MV, need for renal
replacement therapy (RRT), late-onset ventilator-associated pneumonia (VAP), and cardiovascular complications.
ICU mortality during the observation period was 36.1% (141/391). Similar results were obtained by the multivariate logistic
regression analysis using mortality as a dependent variable.
Conclusions: Age, SOFA score at ICU admission, CRS, PaO2/FiO2, renal and cardiovascular complications, and late-onset
VAP were all independent risk factors for prolonged mechanical ventilation in patients with COVID-19.
Trial registration: NCT04411459
Keywords: Coronavirus disease 2019, Intensive care, Mechanical ventilation, Outcomes, mortality, Respiration, artificial,
ARDS
Introduction
A large proportion of patients with coronavirus disease
2019 (COVID-19) develop severe respiratory failure re-
quiring admission to the intensive care unit (ICU) and
about 80% of them need mechanical ventilation (MV) [1].
The reported mortality rate of mechanically ventilated
patients with COVID-19 ranges from 30 to 97% [2–6].
Such a large variability may—at least in part—be due to the
fact that a large portion of patients was still on mechanical
ventilation in most of these studies. It is therefore relevant
to identify the risk factors associated with a longer duration
of mechanical ventilation. Of note, COVID-19 patients
show great complexity due to multiple organ involvement,
such as the lung, heart, kidney, and nervous system [7]. All
these clinical features can contribute to the inability to lib-
erate patients from MV. This may be particularly relevant
since the majority of studies to date are focused mostly on
admission clinical variables. Therefore, since COVID-19 is
characterized by a dynamic evolution over time [8], few in-
formation is available on the risk factors that may contrib-
ute to increase the time course of mechanical ventilation,
delaying the recovery to spontaneous ventilation.
The primary objective of this study is to investigate
the risk factors associated with the inability to liberate
COVID-19 patients from mechanical ventilation. Due to
the complex evolution of the disease, we analyzed both
pulmonary variables and the occurrence of non-
pulmonary complications during mechanical ventilation.
Methods
We conducted a prospective multicenter observational
study in 15 ICUs. All consecutive patients with
laboratory-confirmed SARS-CoV-2 infection admitted to
participating dedicated COVID-19 ICUs from the 22nd
of February through the 4th of May (the end of the
nation-wide lockdown in Italy) 2020 were screened for
eligibility. The clinical outcomes were monitored up to
May 15, the final date of follow-up.
Inclusion and exclusion criteria
Patients older than 18 years who received invasive mech-
anical ventilation were considered as eligible. Inclusion
criteria were (a) SARS-CoV-2 infection confirmed by real-
time reverse transcription-polymerase chain reaction
assays from either nasal swabs or lower respiratory tract
samples [9] and (b) use of invasive mechanical ventilation
at any time of the clinical course. Exclusion criteria were
(a) not a laboratory-confirmed SARS-CoV-2, (b) use of
extracorporeal membrane oxygenation (ECMO) and/or
extracorporeal CO2 removal (ECCO2R), (c) use of non-
invasive ventilation during the entire clinical course, and
(d) cardiac arrest before intubation.
Patients with missing data for the variables of interest (co-
morbidities, length of mechanical ventilation, ventilatory pa-
rameters during the first 5 days, ICU complications, and
discharge information) were not included in the final analysis.
The study was approved by the Institutional Review Board
(IRB) of the study coordinator center (Maggiore Hospital,
Bologna, Italy, approval number: 273/2020/OSS/AUSLBO)
and by each institutional review committee of the participat-
ing hospitals. Informed consent was partially waived accord-
ing to the approval of the local ethics committee, and
researchers analyzed anonymized individual data. The study
was registered in ClinicalTrials.gov (NCT04411459).
Data collection
A list of clinical variables was defined before the initiation
of the study using a priori designed case report forms.
Data were collected by one investigator of each hospital in
an electronic case report form developed by YGHEA,
CRO division of Ecol Studio SPA (Bologna Operational
Headquarters), and hosted by ACTide Nubilaria (Novara,
Italy). Collected data comprised demographic data, infor-
mation on clinical symptoms, or signs at presentation,
underlying comorbidities, laboratory findings, imaging
studies, and respiratory parameters before the intubation
and ventilator setting during the first 5 days of mechanical
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ventilation (e.g., positive end-expiratory pressure (PEEP),
plateau pressure (Pplat), static compliance (CRS), PaO2/
FiO2 ratio), and clinical outcomes. Additional details on
collected variables are available in the online supplement.
Outcome variables
Ventilator-free days at day 28 was the primary outcome
variable. Risk factors associated with ICU mortality were
also assessed.
Definitions
Mechanical ventilation was considered invasive if deliv-
ered through an endotracheal tube or a tracheostomy.
The duration of mechanical ventilation was defined as
the time elapsed from intubation to extubation or suc-
cessful disconnection from mechanical ventilation for
tracheostomized patients. Extubation failure was defined
as the need for reintubation within 48 h, and the time
from failed extubation to reintubation was recorded.
ARDS was classified into three increasing levels of
oxygenation failure into mild, moderate, and severe, ac-
cording to the Berlin definition of ARDS [10].
For respiratory system compliance, we chose a cut-off
of 40 ml/cmH2O for discriminating between higher and
lower compliance. This cut-off was previously proposed
in the Berlin definition of ARDS as an ancillary variable
for defining the most severe cases [10].
Ventilator-free days (VFDs) were defined as a time frame
of 28 days from intubation. For intubated patients, in case
of reintubation within 28 days, VFDs were counted from
the last successful extubation. The use of non-invasive ven-
tilation (NIV) after extubation was not considered as a ven-
tilation period. Finally, zero VFDs were assigned to 28-day
non-survivors, regardless of their intubation status [11]. In
tracheostomized patients, interval disconnections were not
counted and VFDs started after the last successful discon-
nection from mechanical ventilation [11].
Statistical analysis
Data were analyzed using Stata/SE 15.1 (College Station,
Texas, USA); continuous variables were expressed as the
median and interquartile range (IQR); comparisons between
continuous variables were performed with Mann-Whitney
U test; categorical variables were expressed as numbers and
percentages and compared using chi-squared test.
The liberation from MV at 28 days was studied by per-
forming a competing risks regression model on data, ac-
cording to the method of Fine and Gray; the event death
was considered as a competing risk [11].
Model building was performed by means of a variable
selection based on an initial screening using univariate
analysis with p < 0.2 criteria, then a stepwise selection
with entry criteria = 0.05 and stay criteria = 0.1.
Estimates of coefficients in the model are reported as
sub-hazard ratios along with the graphs of the cumula-
tive incidence function of liberation from MV on the
basis of either static compliance of the respiratory sys-
tem or PaO2/FiO2 ratio range adjusted for the other co-
variates introduced into the multivariate model.
Univariate and multivariable logistic regression ana-
lyses were performed in order to evaluate factors associ-
ated with death during ICU stay. Screened risk variables
and model building were the same as for competing
risks regression. The area under the receiver operator
characteristic (ROC) was reported.
In all analyses, the standard errors were adjusted con-
sidering enrolling centers as clusters; therefore, assuming
that observations were independent across different hos-
pitals but not necessarily within the same center. All p
values refer to two-tailed tests of significance and p <
0.05 was considered significant.
Results
Population
Over the study period, 607 patients were screened for eligi-
bility. Patients excluded for admission for other causes than
respiratory failure, use of ECMO/ECCO2R, use of non-
invasive ventilation during the entire clinical course, and
cardiac arrest before intubation were 48, 11, 67, and 6, re-
spectively. Eighty-four patients had missing data for the var-
iables of interest and were not included for the final
analysis. Three hundred ninety-one patients were therefore
included in the final analysis (figure S1, online supplement).
Main demographics, comorbidities, and clinical char-
acteristics at ICU admission are detailed in Table 1. The
patients were predominantly male (300/391, 77%), with
a median [IQR] age of 66 years [59-72]. Hypertension
was the most common comorbidity (222/391, 57%).
Non-invasive ventilation or CPAP was applied in 254
patients (65%) before tracheal intubation. Fifty-four of
them (21% of patients receiving NIV/CPAP) received NIV
in the ICU for more than 24 h. Patients were intubated
after a median of 2 [1–5] days from hospital admission.
Before starting MV, the median PaO2/FiO2 ratio was 94
[75 - 119] mmHg. Initial respiratory parameters showed a
median positive end-expiratory pressure (PEEP) of 12 [10
- 14] cmH2O which resulted in a static respiratory system
compliance (CRS) of 38mL/cmH2O [31 - 47]. During the
first 5 days of mechanical ventilation, the lowest recorded
PaO2/FiO2 ratio was 100 [76 – 132]. Almost all patients
(96.2%) had a PaO2/FiO2 ratio lower than 200. Tracheos-
tomy was performed in 224 patients (57.3%) with a me-
dian time from orotracheal intubation to tracheostomy of
9 [5 - 12] days. Two-hundred fifty-eight patients (66.0%)
were treated with at least one cycle of prone positioning
and 365 patients (93%) received a continuous infusion of
neuromuscular blocking agents (NMBA) for at least 24 h
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MV 28 days (n = 165)
Unsuccessful liberation from
MV 28 days (n = 226)
p
Variables
Age - year (IQR) 66 (59–72) 64 (56–70) 68 (62–74) < 0.001
Sex - male – no (%) 300 (76.7%) 121 (73.3%) 179 (79.2%) 0.175
BMI - median (IQR) 28 (26–31) 28 (26–31) 28 (26–31) 0.918
SAPS II score 38 (31–46) 35 (28–42) 39 (33–48) < 0.001
SOFA score at ICU admission 5 (3–7) 4 (3–6) 6 (4–8) < 0.001
Comorbidities
Hypertension - no (%) 222 (56.8%) 79 (47.9%) 143 (63.3%) 0.003
Chronic ischemic heart disease - no (%) 35 (9.0%) 12 (7.3%) 23 (10.2%) 0.416
Chronic kidney disease (CKD) 26 (6.6%) 8 (4.8%) 18 (8.0%) 0.362
CKD - patients in dialisys - no (%) 4 (1.0%) 1 (0.6%) 3 (1.3%)
COPD - no (%) 27 (6.9%) 11 (6.7%) 16 (7.1%) 0.964a
COPD - home oxygen therapy/CPAP - no (%) 2 (0.5%) 1 (0.6%) 1 (0.4%)
Diabetes - no (%) 85 (21.7%) 28 (17.0%) 57 (25.2%) 0.067
Chronic liver disease (MELD > 10) - no (%) 3 (0.8%) 1 (0.6%) 2 (0.9%) 1.000
Active cancer - no (%) 7 (1.8%) 0 (0%) 7 (3.1%) 0.058
Immunosuppressive therapy - no (%) 10 (2.6%) 1 (0.6%) 9 (4.0%) 0.078
Smoker status (n = 213) b
Current - no (%) 13 (6.1%) 8 (8.1%) 5 (4.4%) 0.507a
Previous - no (%) 66 (31.0%) 29 (29.3%) 37 (32.5%)
Characteristics before ICU admission
Time from symptoms onset to hospital admission
(n = 327)b - d (IQR)
7 (4–9) 7 (4–9) 7 (4–10) 0.480
Time from hospital admission to ICU admission - d (IQR) 2 (1–5) 2 (1–5) 2 (0–5) 0.436
Time from hospital admission to intubation - d (IQR) 2 (1–5) 2 (1–5) 2 (1–6) 0.389
Ward of admission
Emergency department - no (%) 70 (17.9%) 20 (12.1%) 50 (22.1%) 0.04a
Medical ward - no (%) 184 (47.1%) 82 (49.7%) 102 (45.1%)
Other ICU - no (%) 137 (35.0%) 63 (38.2%) 74 (32.7%)
High flow nasal oxygen therapy before intubation
(n = 362)b - no (%)
31 (8.5%) 14 (9.1%) 17 (8.1%) 0.880
CPAP/Non-invasive ventilation trial before intubation
(n = 363)b - no (%)
254 (70%) 117 (70.9%) 137 (60.6%) 0.029
Duration of CPAP/NIV trial (n = 363)b
< 12 h - no (%) 56 (22.1%) 24 (20.5%) 32 (23.5%) 0.051a
12–24 h - no (%) 63 (24.9%) 35 (29.9%) 28 (20.6%)
24–48 h - no (%) 44 (17.4%) 25 (21.4%) 19 (14.0%)
> 48 h - no (%) 90 (35.6%) 33 (28.2%) 57 (41.9%)
PaO2/FiO2 ratio before intubation (n = 297)
b 94 (75–119) 96 (71–125) 91 (77–116) 0.544
Abbreviations: IQR interquartile range, BMI body mass index, SAPS simplified acute physiology score, SOFA Sequential Organ Failure Assessment Score,
CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CPAP continuous positive airway pressure, MELD model for end-stage liver
disease, NIV non-invasive ventilation, PaO2 arterial oxygen partial pressure, FiO2 inspired fraction of oxygen
ap value referred to Pearson’s chi-square test performed on the contingency table represented
bIncomplete data due to transfer from other ICUs without complete medical records
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(see Table S1, online supplement for further details about
adjunctive treatments) (Table 2).
In this cohort, 216 patients (55.2%) experienced at
least one non-pulmonary complication, the most fre-
quent being acute kidney injury needing renal replace-
ment therapy (76 patients,19.4%) and cardiovascular
complications (66 patients, 16.9%).
Among pulmonary complications, the most frequent
was the late-onset ventilator-associated pneumonia (175
patients, 44.8%). Table S2 (online supplement) describes
the specific complications observed.
During the period of observation, liberation from MV
was achieved in 208 patients (53.2%) after a mean dur-
ation of MV of 14 [9 – 19] days. Clinical characteristics,
as well as respiratory parameters and occurrences of
non-pulmonary organ failure, are reported in Table 2.
Initial ventilatory variables did not show differences be-
tween groups. During the first 5 days of MV, both PaO2/
FiO2 ratio and CRS were significantly higher in patients
who achieved a successful liberation.
Competing risks analysis demonstrated a decreased
sub-hazard ratio (SHR) for liberation from mechanical
ventilation with increasing age and SOFA score at ICU
admission, with decreasing lowest PaO2/FiO2 ratio and
CRS lower than 40mL/cmH2O during the first 5 days of
MV, need for renal replacement therapy (RRT) during
ICU stay, late-onset ventilator-associated pneumonia
(VAP), and cardiovascular complications. Univariate and
multivariate analyses for liberation from mechanical ven-
tilation are presented in Table 3.
Figure 1 shows the cumulative incidence function of
28-day liberation from mechanical ventilation divided
for classes of worst CRS or PaO2/FiO2 ratio observed
within the first 5 days of MV and adjusted for the sig-
nificant covariates defined in Table 3.
Secondary outcome
Multivariate logistic regression analysis using mortality
as a dependent variable showed that increasing age,
higher SOFA score at ICU admission, need for renal re-
placement therapy during ICU stay, cardiovascular com-
plications, lower PaO2/FiO2 ratio, and low CRS during
the first 5 days of invasive MV were independently asso-
ciated to ICU mortality. Table 4 shows the results of
univariate and multivariate analyses on the abovemen-
tioned variables (see Figure S2 online supplement for
the ROC curve).
Discussion
The main findings of this prospective analysis are (a) in-
vasively ventilated COVID-19 patients exhibited both a
long duration of mechanical ventilation and ICU length
of stay; (b) age, SOFA score, PaO2/FiO2 ratio, CRS, acute
kidney injury (requiring renal replacement therapy), late
pulmonary infections, and cardiovascular complications
were all independent risk factors for prolonged mechan-
ical ventilation; and (c) our patients’ population had
PaO2/FiO2 and CRS values resembling those of “classical”
(i.e., non-COVID-19 related) ARDS.
Most observational studies published until now on
COVID-19 patients investigated the risk factors for hos-
pital mortality, whereas our aim was to focus on risk fac-
tors responsible for prolonged mechanical ventilation.
The risk factors we identified may be classified into
three main categories: demographics and baseline sever-
ity, physiology, and complications during the ICU stay.
Among demographical variables, increasing age was
significantly associated with a higher duration of MV
and ICU mortality and this is in line with recent litera-
ture on COVID-19 patients [12], but also on “classical”
ARDS patients [2, 13]. As for baseline severity, SOFA
score at ICU admission, but not SAPS II score, was in-
versely associated to an increased SHR for liberation
from mechanical ventilation at 28 days and directly asso-
ciated to death in the multivariate competing risk and
logistic analyses [2, 14, 15].
Considering the physiological characteristics of the pa-
tients, most of them exhibited a reduced static compli-
ance. A CRS < 40 mL/cmH2O was previously proposed
in the Berlin definition of ARDS as an ancillary variable
for defining the most severe cases [10]; moreover, this
cut-off has been recently proposed to identify a more se-
vere phenotype of COVID-19 [16]. In our patients, CRS
< 40mL/cmH2O was independently associated with both
prolonged mechanical ventilation (Fig. 1) and mortality.
In this regard, we also showed that 55% of patients had
CRS < 40mL/cmH2O at starting of MV, while 57% of pa-
tients experienced CRS < 40mL/cmH2O during the first
5 days. Of note, CRS after intubation did not differ be-
tween patients who were or not liberated from MV but
the percentage of patients with CRS < 40 mL/cmH2O
within 5 days was significantly different. Although our
data do not allow definite conclusions, we can underline
that a CRS < 40 mL/cmH2O possibly represents a marker
of worse ventilatory outcome in COVID-19 patients.
As expected from current knowledge on COVID-19
[17], oxygenation was compromised and a high FiO2
(median value 70%) was needed. Further, the lowest
PaO2/FiO2 ratio observed during the first 5 days of MV
was a limiting factor for liberation from mechanical ven-
tilation, as it has been demonstrated in “classical” ARDS
patients [2, 18, 19].
The debate on whether COVID-19 patients have a
special form of ARDS is still ongoing [17, 20], but recent
papers focused on COVID-19-ARDS pathophysiology
report values of oxygenation (P/F ratio) and compliance
similar to those of “classical” ARDS [12, 19, 21–23]. The
totality of our patients matches oxygenation criteria for
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Table 2 Main results—ICU ventilation data, complications, and outcomes




Initial ventilatory variables a n = 240 a n = 93 a n = 147 a p
Tidal volume set - mL/kg IBW (IQR) 7.1 (6.5–7.8) 7 (6.5–7.9) 7.1 (6.4–7.7) 0.932
PEEP set - cmH2O (IQR) 12 (10–14) 12 (10–14) 12 (10–14) 0.466
Pplat - cmH2O (IQR) 25 (22–27) 25 (22–27) 25 (22–28) 0.662
CRS in supine position - mL/cmH2O (IQR) 38 (32–47) 39 (32–48) 37 (31–47) 0.297
CRS in supine position < 40mL/cmH2O – no (%) 132 (55%) 49 (52.7%) 83 (56.5%) 0.567
Mechanical ventilation - first 5 days n = 391 n = 165 n = 226 p
Highest FiO2 set for at least 12 h - % (IQR) 70 (60–80) 70 (60–80) 75 (60–90) < 0.001
Lowest PaO2/FiO2 ratio in supine position - (IQR) 100 (76–132) 113 (90–145) 94 (68–123) < 0.001
PaO2/FiO2 class < 0.001
b
200–300 - no (%) 15 (3.8%) 6 (3.6%) 9 (4.0%)
100–200 - no (%) 195 (49.9%) 106 (64.2%) 89 (39.4%)
< 100 - no (%) 181 (46.3%) 53 (32.1%) 128 (56.6%)
Lowest static CRS - mL/cmH2O (IQR) 37 (30–45) 40 (33–47) 35 (30–43) < 0.001
CRS < 40mL/cmH2O - no (%) 225 (57.5%) 77 (46.7%) 148 (65.5%) < 0.001
ICU stay variables n = 391 n = 165 n = 226 p
Liberation from mechanical ventilation - no (%) 208 (53.2%) 165 (100%) 43 (19%) –
VFD 28 days - d (IQR) 14 (9–19) 14 (9–19) 0 –
Duration of MV - d (IQR) 16 (10–27) 14 (9 –19) 20 (11–33) < 0.001
Alivec (n = 250) – d (IQR) 17 (10–30) 14 (9–19) 35 (29–46.5) < 0.001
Extubation - no (%) 89 (22.8%) 81 (49%) 8 (3.5%) < 0.001
Tracheotomy - no (%) 224 (57.3%) 83 (50.3%) 141 (62.4%) 0.022
Time from first tracheal intubation to tracheotomy - d (IQR) 9 (5–12) 7 (4–11) 9 (6–13) 0.002
Length of ICU stay - days (IQR) 20 (13–32) 18 (14–27) 21 (11–38) 0.111
Alived (n = 250) - days (IQR) 24 (15–38) 18 (14–27) 42 (32–51) < 0.001
Dead (n = 141) - days (IQR) 15 (8–22) 0 15 (8–22) –
Post extubation eventsc n = 89 n = 81 n = 8 p
Extubation failure within 48 h - no (%) 9 (10.1%) 5 (6.1%) 4 (50%) < 0.001
Extubation failure over 48 h - no (%) 7 (7.9%) 3 (3.7%) 4 (50%) < 0.001
NIV/CPAP after extubation - no (%) 51 (57.3%) 43 (53%) 8 (100%) 0.017
HFNO after extubation - no (%) 5 (5.6%) 9 (11%) 1 (12.5%) 0.980
ICU Complications n = 391 n = 165 n = 226 p
Cardiovascular - no (%) 66 (16.9%) 10 (6.1%) 56 (24.8%) < 0.001
Neurologic - no (%) 25 (6.4%) 7 (4.2%) 18 (8.0%) 0.137
Gastroenteric - no (%) 20 (5.1%) 6 (3.6%) 14 (6.2%) 0.257
Need for renal replacement therapy - no (%) 76 (19.4%) 13 (7.9%) 63 (27.9%) < 0.001
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ARDS, most of them exhibit impaired lung mechanics (low
static compliance) and need treatment with relatively high
levels of PEEP (median 12 cmH2O) [24] and FiO2 (median
70%) to warrant adequate oxygenation, all characteristics
common to “classical” ARDS [25]. This may explain why
most of the risk factors for prolonged mechanical
ventilation we have identified are common to those of
ARDS due to other causes. Of course, some features of
ARDS due to COVID-19 seem to be peculiar and particu-
larly important in determining the outcome. One of the
main histological findings in COVID-19 ARDS is a signifi-
cant endothelial involvement due to viral antigen exposure
Table 2 Main results—ICU ventilation data, complications, and outcomes (Continued)




Early onset VAP - no (%) 76 (19.4%) 29 (17.6%) 47 (20.8%) 0.427
Lateonset VAP - no (%) 175 (44.8%) 49 (29.7%) 126 (55.8%) < 0.001
Non-pulmonary infections - no (%) 112 (28.6%) 35 (21.2%) 77 (34.1%) 0.005
Still in ICU at the end of observation - no (%) 39 (9.7%) 4 (2.4%) 35 (15.5%) < 0.001
ICU mortalityd - no (%) 141 (36.1%) 0 (0%) 141 (62.4%) < 0.001
Abbreviations: IBW ideal body weight, PEEP positive end-expiratory pressure, Pplat plateau pressure, CRS respiratory system compliance measured in a supine
position, FiO2 inspired fraction of oxygen, PaO2 arterial oxygen partial pressure, MV mechanical ventilation, NIV non-invasive ventilation, CPAP continuous positive
airway pressure, HFNO high flow nasal oxygen, VFD ventilator-free days, VAP ventilator-associated pneumonia
aIncomplete data due to transfer from other ICUs without complete medical records
bp value referred to Pearson’s chi-square test performed on the contingency table represented cThe percentages of extubation failures and NIV/CPAP/HFNO use
after extubation are referred to the total number of the patients extubated
dPatients discharged alive from ICU or still in ICU at the end of observation
Table 3 Fine and Gray’s competing-risks analysis
Univariate analysis Multivariate analysis
Variable SHR 95% CI p SHR 95% CI p
Age 0.968 0.959–0.978 < 0.001 0.979 0.966–0.992 0.002
Sex (M) 0.716 0.491–1.044 0.083 –
BMI 0.999 0.974–1.024 0.922 –
SOFA score at ICU admission 0.836 0.788–0.887 < 0.001 0.867 0.792–0.949 0.002
SAPS II score 0.973 0.959–0.987 < 0.001 –
Hypertension 0.648 0.498–0.843 0.001 –
Chronic ischemic heart disease 0.760 0.473–1.221 0.257 –
COPD (oxygen therapy/CPAP) 0.982 0.219–4.407 0.981 –
Chronic kidney disease (CKD) 0.692 0.303–1.582 0.383 –
CKD –dialisys 0.532 0.061–4.640 0.568 –
Diabetes 0.703 0.459–1.078 0.106 –
Chronic liver disease (MELD > 10) 0.853 0.224–3.239 0.815 –
Renal replacement therapy during ICU stay 0.274 0.142–0.531 < 0.001 0.381 0.220–0.660 0.001
Early onset VAP 0.844 0.600–1.188 0.331 –
Late-onset VAP 0.357 0.251–0.510 < 0.001 0.283 0.197–0.407 < 0.001
Lowest PaO2/FiO2 within 5 days
a 1.729 1.312–2.280 < 0.001 1.631 1.316–2.023 < 0.001
CRS < 40mL/cmH2O within 5 days 0.538 0.350–0.826 0.005 0.488 0.317–0.752 0.001
Cardiovascular complications 0.253 0.175–0.367 < 0.001 0.277 0.181–0.423 < 0.001
Neurologic complications 0.550 0.236–1.283 0.167 0.469 0.207–1.061 0.069
Gastrointestinal complications 0.578 0.374–0.894 0.014 –
Extrapulmonary infections 0.533 0.326–0.872 0.012 –
Notes: Event of interest—liberation from mechanical ventilation. Competing event- death. Observation time: 28 days
Abbreviations: SHR subhazard ratio, BMI body mass index, SAPS simplified acute physiology score, SOFA Sequential Organ Failure Assessment Score, COPD chronic
obstructive pulmonary disease, CKD chronic kidney disease, MELD model for end-stage liver disease, PaO2 arterial oxygen partial pressure, FiO2 inspired fraction of
oxygen, CRS respiratory system compliance
aSHR calculated per 100 points increase of PaO2/FiO2 ratio
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Fig. 1 Cumulative incidence function of liberation from mechanical ventilation on the divided for either static compliance of the respiratory
system (CRS) or PaO2/FiO2 ratio range and adjusted for the other covariates introduced into the multivariate model of the competing-risks regression
Table 4 Multivariate logistic regression analysis, dependant variable death during ICU stay
Univariate logistic regression analysis Multivariate logistic regression analysis
Variable HR 95% C.I. p HR 95% C.I. p
Age 1.067 1.029–1.107 < 0.001 1.073 1.032–1.116 < 0.001
Sex (M) 1.120 0.735–1.709 0.597 –
BMI 0.992 0.945–1.042 0.761 –
SOFA score at ICU admission 1.215 1.095–1.349 < 0.001 1.142 1.007–1.295 0.038
SAPS II score 1.042 1.022–1.063 < 0.001 –
Hypertension 1.906 1.182–3.073 0.008 –
Chronic ischemic heart disease 1.053 0.556–1.992 0.875 –
COPD (oxygen therapy/CPAP) 1.454 0.060–35.34 0.818 –
Chronic kidney disease (CKD) 1.599 0.706–3.617 0.260 –
CKD – dialisys 5.595 0.512–61.132 0.158 –
Diabetes 3.583 0.793–16.195 0.097 –
Chronic liver disease (MELD > 10) 3.583 0.793–16.195 0.097 –
Renal replacement therapy during ICU stay 2.885 2.265–3.675 < 0.001 2.115 1.037–4.310 0.039
Early onset VAP 1.574 0.797–3.108 0.192 –
Late-onset VAP 1.190 0.787–1.812 0.410 –
Lowest PaO2/FiO2 within 5 days
a 0.396 0.248–0.631 < 0.001 0.383 0.239–0.613 < 0.001
CRS < 40mL/cmH2O within 5 days 2.844 2.221–3.642 < 0.001 3.193 2.525–4.040 < 0.001
Cardiovascular complications 4.701 2.807–7.874 < 0.001 4.600 2.474–8.554 < 0.001
Neurologic complications 0.673 0.233–1.947 0.465 –
Gastrointestinal complications 0.749 0.288–1.952 0.555 –
Extrapulmonary infections 0.877 0.488–1.578 0.662 –
Notes: AUC of the ROC curve for the multivariate model: 0.818
Abbreviations: HR hazard ratio, C.I. confidence interval, BMI body mass index, SAPS simplified acute physiology score, SOFA Sequential Organ Failure Assessment
Score, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, MELD model for end-stage liver disease, VAP ventilator-associated pneumonia,
PaO2 arterial oxygen partial pressure, FiO2 inspired fraction of oxygen, CRS respiratory system compliance
aPer 100 points increase of PaO2/FiO2 ratio
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and cytokine activation that leads to inflammation activa-
tion and possible cytokine storm, mostly through the acti-
vation of an angiotensin-converting enzyme 2 (ACE2)
receptor (expressed in pulmonary endothelial cells, alveolar
epithelial type II cells, heart, intestine, and kidney). This
histological damage can in part explain the prothrombotic
state of COVID-19 patients, and it has been observed that
higher D-dimer levels correlate with the severity of the dis-
ease and the in-hospital mortality [26]; moreover, very high
mortality rates have been observed if high D-dimer levels
are combined with low static compliance values [22].
The third category of risk factors for prolonged mech-
anical ventilation we identified is represented by the
complications during ICU stay. Indeed, the survival out-
come of mechanically ventilated patients depends not
only on baseline characteristics but also on further de-
velopment of complications. These can be further subdi-
vided into non-pulmonary and pulmonary. Among non-
pulmonary complications, the most frequent were acute
kidney injury needing renal replacement therapy (19%)
and cardiovascular events (17%).
Acute kidney injury has already been described in
COVID-19 patients; although pathophysiological mecha-
nisms should be further characterized, SARS-CoV-2 seems
to affect the kidney directly or indirectly [27, 28]. The cause
of kidney involvement in COVID-19 is likely to be multi-
factorial: endothelial damage due to virus particles, an
ACE2-dependent pathway causing cellular dysfunction, and
immune response dysregulation in a hypercoagulability and
endotheliitis state are probably the most important con-
tributor to acute kidney injury [29–31]. Patients developing
acute kidney injury during ICU stay frequently have comor-
bidities [32, 33], and they usually have less favorable out-
come [33] and easily develop complications related to fluid
overload [34]; consequently, acute kidney injury is a known
risk factor for prolonged mechanical ventilation in critically
ill patients, regardless of the underlying disease [35, 36].
A high rate of cardiovascular events in COVID-19 pa-
tients has already been reported [37–39]; in particular,
myocardial injury was described in 7.2% of patients overall
and in 22% of patients requiring ICU admission [40], a per-
centage similar to the one recorded in our study (17%). The
pathophysiologic mechanisms are still unclear, the most
probably being (a) the direct viral action on the myocar-
dium (i.e., SARS-CoV-2 myocarditis) and (b) the cardiomy-
opathy caused by cytokine storm (similar to septic
cardiomyopathy) [37]. Our data show that cardiovascular
complications are a strong predictor not only of mortality,
but also of delayed separation from mechanical ventilation.
Among pulmonary complications, infections played a
major role. Late-onset ventilator-associated pneumonia
(VAP) had a relevant incidence (44.8%) in our patients,
considerably higher than that observed in other studies
on “classical” ARDS [41]. This result could be explained
by the frequent use of immunomodulatory agents as ad-
junctive therapies [42] or to SARS-CoV-2 infection per
se [43] (see supplement Table 1). Although the descrip-
tion of incidence, risk factors, and microbiology of late-
onset VAP goes beyond the aims of this study, we be-
lieve that this aspect can be of clinical relevance, deserv-
ing future studies.
Besides the high incidence of VAP, the high rate of
tracheostomy may be related to the length of MV and the
relatively high incidence of reintubation. The median dur-
ation of invasive ventilation in our COVID-19 patients was
16 days, and this is in line with other recent reports, show-
ing a range of 10–18 days [12, 19, 21, 23]; meanwhile, in
“classical” ARDS durations between 6 days for mild and 11
days for severe ARDS have been reported [2]. The reason
for this discrepancy has to be further investigated, but we
can formulate some hypotheses: first, ARDS patients in the
LUNG-SAFE cohort were much more heterogeneous than
our cohort of viral pneumonias due to SARS-CoV-2 infec-
tion; second, in COVID-19 patient, the involvement of the
central nervous system [44], heart [45], and kidney [30] is
frequent, thus explaining the longer need for mechanical
ventilation and the noticeably long ICU length of stay (me-
dian 20 days overall, 24 days in surviving patients) we re-
corded in our population. Indeed, 57.3% of the patients
underwent tracheostomy within a median of 9 days [5–12]
from intubation. Although a precise definition of “early”
and “late” tracheostomy is still lacking, our patients can be
placed in the upper range of early tracheostomy, according
to previous trials [46, 47]. To date, no guidelines exist on
the optimal timing of tracheostomy in COVID-19 patients,
although an expert consensus suggests delaying tracheos-
tomy at least 10 days after intubation [48].
This study has some limitations. First, although data
collection was prospective, ventilatory treatment and
weaning were not standardized among participating cen-
ters, thus adding potential confounding factors. Second,
for many variables, we asked the participating centers to
collect the lowest values in the first 5 days of ICU stay,
thus possibly missing valuable data on the precise time-
course of these variables. Third, various experimental
COVID-19 therapies were tested in different centers
during the conduction of this study (see Table S1, online
supplement). In order to control for the center-related
effects, clusterization was adopted for statistical analysis.
Finally, 22 patients had not completed the observation
period for outcome measures, either because they were
still in the ICU at the end of the observation period or
because they were transferred for logistical reasons to
other non-participating ICUs; in any case, censoring be-
fore the end of observation was taken into account by
competing risks regression analysis.
Even though regional and national healthcare systems
were experiencing high levels of stress at the time of data
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collection, no rationing of healthcare resources [49] was in
place in any participating center. Accordingly, although
organizational issues do not fall within the scope of this
paper, we can exclude that organizational issues may have
contributed to unfavorable outcomes.
Despite these limitations, to the best of our knowledge,
this is the first study to elucidate the risk factors associated
with prolonged mechanical ventilation in COVID-19
patients. Our findings may help clinicians predict the risk
for prolonged mechanical ventilation. Once patients with
multiple risk factors are identified, clinicians should con-
sider the possibility of a high failure rate of life-sustaining
interventions and discuss the possible shift towards a
palliative approach. Such a decision should be rigorous
and comprehensive of all clinical information. However,
additional large-scale studies are still warranted to validate
our findings.
Conclusions
Patients with COVID-19 exhibited a high risk of failure
from MV liberation at 28 days. Age, SOFA score, PaO2/
FiO2 ratio, CRS, need for renal replacement therapy, late-
onset VAP, and cardiovascular complications were all inde-
pendent risk factors for prolonged mechanical ventilation.
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